JP2015517463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517463A5 JP2015517463A5 JP2015510278A JP2015510278A JP2015517463A5 JP 2015517463 A5 JP2015517463 A5 JP 2015517463A5 JP 2015510278 A JP2015510278 A JP 2015510278A JP 2015510278 A JP2015510278 A JP 2015510278A JP 2015517463 A5 JP2015517463 A5 JP 2015517463A5
- Authority
- JP
- Japan
- Prior art keywords
- candidate compounds
- aureus infection
- cd11b
- lukab
- aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641543P | 2012-05-02 | 2012-05-02 | |
| US61/641,543 | 2012-05-02 | ||
| PCT/US2013/032436 WO2013165613A1 (en) | 2012-05-02 | 2013-03-15 | Methods of treating and preventing staphylococcus aureus infections and associated conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517463A JP2015517463A (ja) | 2015-06-22 |
| JP2015517463A5 true JP2015517463A5 (https=) | 2016-04-21 |
Family
ID=49514732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510278A Pending JP2015517463A (ja) | 2012-05-02 | 2013-03-15 | 黄色ブドウ球菌感染および関連状態を処置および予防する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9657103B2 (https=) |
| EP (1) | EP2844287A4 (https=) |
| JP (1) | JP2015517463A (https=) |
| CN (1) | CN104428000A (https=) |
| AU (1) | AU2013257161B2 (https=) |
| CA (1) | CA2871152A1 (https=) |
| HK (1) | HK1207981A1 (https=) |
| IL (1) | IL235284A0 (https=) |
| WO (1) | WO2013165613A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160108106A1 (en) * | 2013-05-21 | 2016-04-21 | Arsanis Biosciences Gmbh | Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus |
| WO2016197071A1 (en) * | 2015-06-05 | 2016-12-08 | New York University | Compositions and methods for anti-staphylococcal biologic agents |
| US11685785B2 (en) * | 2015-06-12 | 2023-06-27 | Ascendo Biotechnology, Inc. | Methods and antibodies for modulation of immunoresponse |
| EP3638286A4 (en) * | 2017-06-13 | 2021-03-10 | Integrated Biotherapeutic Vaccines, Inc. | IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS |
| US12291562B2 (en) | 2019-04-01 | 2025-05-06 | Rush University Medical Center | Reagents and assays using modified integrin domains |
| CN114437187B (zh) * | 2022-02-09 | 2023-06-20 | 淮北师范大学 | 一种细菌素Bacin A4及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5602299A (en) | 1992-09-23 | 1997-02-11 | Mount Sinai School Of Medicine Of The City University Of New York | Transgenic animal models for neurodegenerative disease |
| JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
| US6066778A (en) | 1996-11-06 | 2000-05-23 | The Regents Of The University Of Michigan | Transgenic mice expressing APC resistant factor V |
| US20030162956A1 (en) | 1997-04-07 | 2003-08-28 | Human Genome Sciences, Inc. | Leukocyte regulatory factors 1 and 2 |
| EP1311282A4 (en) * | 2000-07-31 | 2005-07-13 | Gen Hospital Corp | HIGH AFFINIT INT-GRIN POLYPEPTIDES AND USES THEREOF |
| US7323552B2 (en) | 2000-07-31 | 2008-01-29 | The General Hospital Corporation | Variant integrin polypeptides and uses thereof |
| US20040063202A1 (en) * | 2002-08-28 | 2004-04-01 | Petersen Bryon E. | Neurogenesis from hepatic stem cells |
| JP2006094701A (ja) * | 2002-09-17 | 2006-04-13 | Chugai Pharmaceut Co Ltd | ７ｆ４遺伝子トランスジェニック動物 |
| JP4897690B2 (ja) * | 2004-10-12 | 2012-03-14 | ジェネンテック， インコーポレイテッド | 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド |
| WO2006086500A2 (en) | 2005-02-08 | 2006-08-17 | Aspreva Pharmaceuticals Sa | Compositions and methods for treating vascular, autoimmune and inflammatory diseases |
| CA2598029A1 (en) * | 2005-02-24 | 2006-10-05 | The Scripps Research Institute | Isolated myeloid-like bone marrow cell populations and methods of treatment therewith |
| JP5250810B2 (ja) * | 2006-05-31 | 2013-07-31 | 公益財団法人ヒューマンサイエンス振興財団 | ユートロフィン遺伝子発現増強物質のスクリーニング |
| JP2008220174A (ja) * | 2007-03-08 | 2008-09-25 | Tokyoto Igaku Kenkyu Kiko | 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物 |
| US20100310665A1 (en) * | 2007-10-25 | 2010-12-09 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
| MX342270B (es) * | 2010-02-18 | 2016-09-21 | The Regents Of The Univ Of California * | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. |
| RU2677140C1 (ru) * | 2010-05-05 | 2019-01-15 | Нью-Йорк Юниверсити | Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение |
| US9023876B2 (en) * | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| MX357938B (es) | 2011-06-19 | 2018-07-31 | Univ New York | Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas. |
| AU2012273125B2 (en) | 2011-06-19 | 2017-05-25 | New York University | Leukotoxin E/D as a new anti-inflammatory agent and microbicide |
-
2013
- 2013-03-15 US US14/398,293 patent/US9657103B2/en not_active Expired - Fee Related
- 2013-03-15 WO PCT/US2013/032436 patent/WO2013165613A1/en not_active Ceased
- 2013-03-15 CA CA2871152A patent/CA2871152A1/en not_active Abandoned
- 2013-03-15 CN CN201380034208.9A patent/CN104428000A/zh active Pending
- 2013-03-15 HK HK15108668.7A patent/HK1207981A1/xx unknown
- 2013-03-15 EP EP13784426.2A patent/EP2844287A4/en not_active Withdrawn
- 2013-03-15 JP JP2015510278A patent/JP2015517463A/ja active Pending
- 2013-03-15 AU AU2013257161A patent/AU2013257161B2/en not_active Ceased
-
2014
- 2014-10-22 IL IL235284A patent/IL235284A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grousd et al. | Host-pathogen interactions in gram-positive bacterial pneumonia | |
| JP2015517463A5 (https=) | ||
| Freiberg et al. | Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection | |
| Maurer et al. | Autophagy mediates tolerance to Staphylococcus aureus alpha-toxin | |
| Traub et al. | An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation | |
| Watkins et al. | Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus | |
| Gu et al. | Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus | |
| Lin et al. | Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction | |
| Pinar et al. | PB1-F2 peptide derived from avian influenza A virus H7N9 induces inflammation via activation of the NLRP3 inflammasome | |
| Koch et al. | Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b | |
| Zhou et al. | Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis | |
| Keynan et al. | Staphylococcus aureus bacteremia, risk factors, complications, and management | |
| Pincus et al. | Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection | |
| Josefsson et al. | Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence | |
| Wang et al. | Interaction of fibrinogen and muramidase-released protein promotes the development of Streptococcus suis meningitis | |
| Peng et al. | Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer | |
| Rabes et al. | The C-type lectin receptor Mincle binds to Streptococcus pneumoniae but plays a limited role in the anti-pneumococcal innate immune response | |
| Westman et al. | Extracellular histones induce chemokine production in whole blood ex vivo and leukocyte recruitment in vivo | |
| Safronetz et al. | In vitro and in vivo activity of ribavirin against Andes virus infection | |
| Bidula et al. | Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species | |
| Martin-Manso et al. | Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis | |
| Choy | Multiple activities of LigB potentiate virulence of Leptospira interrogans: inhibition of alternative and classical pathways of complement | |
| Smalley et al. | Rickettsia australis activates inflammasome in human and murine macrophages | |
| JP2014527398A5 (https=) | ||
| Hu et al. | GPVI and GPIbα mediate staphylococcal superantigen-like protein 5 (SSL5) induced platelet activation and direct toward glycans as potential inhibitors |